|
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Thus, PCDH17 acts as a tumour suppressor, exerting its anti-proliferative activity through inducing apoptosis and autophagy, and is frequently silenced in gastric and colorectal cancers.
|
22926751 |
2013 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients.
|
26404644 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, PCDH17 methylation in serum is a potential prognostic biomarker for patients with RCC after surgery.
|
28688232 |
2017 |
|
Gastritis, Atrophic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the protein expression analysis, PCDH17 expression was inversely associated with gastric lesions; the OR [95% confidence interval (CI)] was 0.49 (0.26-0.95) for chronic atrophic gastritis (CAG), 0.31 (0.15-0.63) for intestinal metaplasia, and 0.38 (0.19-0.75) for indefinite dysplasia and dysplasia, compared with superficial gastritis.
|
30213786 |
2018 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.
|
31374203 |
2019 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A combined analysis of genetically correlated traits identifies 187 loci and a role for neurogenesis and myelination in intelligence.
|
29326435 |
2019 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function.
|
29844566 |
2018 |
|
Intestinal metaplasia
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In the protein expression analysis, PCDH17 expression was inversely associated with gastric lesions; the OR [95% confidence interval (CI)] was 0.49 (0.26-0.95) for chronic atrophic gastritis (CAG), 0.31 (0.15-0.63) for intestinal metaplasia, and 0.38 (0.19-0.75) for indefinite dysplasia and dysplasia, compared with superficial gastritis.
|
30213786 |
2018 |
|
Laryngeal Squamous Cell Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
And low expression of miR-196b and high expression of PCDH-17 contributed to an increase in the 5-year-survival rate of LSCC patients.
|
30454973 |
2019 |
|
Laryngeal Squamous Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma.
|
21213369 |
2011 |
|
Laryngeal Squamous Cell Carcinoma
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
In conclusion, we provide a mechanistic explanation of recurrently observed PCDH17 silencing in LSCC by demonstrating the role of promoter methylation in this process.
|
29566279 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, low PCDH17 expression predicted worse overall survival (OS) in four independent cohorts as well as in the molecularly defined subgroups of AML patients.
|
30922328 |
2019 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, our results obtained both in vivo and ex vivo suggested that activation of EGFR/MEK/ERK signaling pathway through PCDH-17 promotes metastasis in HCC.
|
26386721 |
2016 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of PCDH17 in breast cancer was mainly due to the methylation of its promoter.
|
27351130 |
2016 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
PCDH17 increases the sensitivity of colorectal cancer to 5-fluorouracil treatment by inducing apoptosis and autophagic cell death.
|
31815010 |
2019 |
|
Malignant neoplasm of nasopharynx
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant promoter methylation reduced the expression of protocadherin 17 in nasopharyngeal cancer.
|
30165032 |
2019 |
|
Malignant neoplasm of ovary
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
PCDH17 methylation was detected in almost 70% of HGSOC patients without any methylation in the group of control samples and was found both in the late stage tumors as well as in the early stage ones.
|
29991130 |
2018 |
|
Malignant neoplasm of prostate
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
In addition, PCDH17 methylation was an independent predictor of poor biochemical recurrence-free (BCR-free) survival and overall survival for patients with prostate cancer.
|
25091018 |
2014 |
|
Malignant neoplasm of stomach
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PCDH17 mRNA expression in pairs of gastric cancer and normal tissue samples and cell lines were determined by quantitative real-time polymerase chain reaction.
|
22207556 |
2012 |
|
Malignant neoplasm of urinary bladder
|
0.050 |
Biomarker
|
disease |
BEFREE |
The combination of POU4F2/PCDH17 has yielded the highest sensitivity and specificity of 90.00% and 93.96% in all the 312 individuals, showing the capability of detecting BlCa effectively among pathologically varied sample groups.
|
26700620 |
2016 |
|
Malignant neoplasm of urinary bladder
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
PCDH17 and TCF21 methylation levels provided a sensitivity rate of 92% for bladder cancer, 67% for renal cell tumors and 96% for prostate cancer.
|
21847011 |
2011 |
|
Malignant neoplasm of urinary bladder
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The p53 mutation, the expression of p53 and PCDH17 were significantly associated with survival from bladder cancer.
|
31772653 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer.
|
24567353 |
2014 |
|
Malignant neoplasm of urinary bladder
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
PCDH17 promoter methylation was significantly associated with malignant behaviour and poor prognosis of bladder cancer.
|
24366498 |
2014 |
|
Malignant Neoplasms
|
0.030 |
PosttranslationalModification
|
group |
BEFREE |
PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer.
|
24567353 |
2014 |